

28 June 2007

To All Pharmaceutical Suppliers, Hospital Pharmacists, Medical Groups and Interested Parties

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254,
Wellington 6143, New Zealand

Phone 64-4-460-4990

Fax 64-4-460-4995

www.pharmac.govt.nz

Consultation on a proposal to list Arrow-Clopidogrel in the Pharmaceutical Schedule

PHARMAC has entered into a provisional agreement with Arrow Pharmaceuticals (NZ) Limited in relation to the listing of clopidogrel (Arrow-Clopidogrel) in the Pharmaceutical Schedule. Details of the proposal are as follows:

- Arrow-Clopidogrel 75 mg tablets would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 March 2008 at the following price and subsidy (ex-manufacturer, excluding GST):

Chemical	Brand	Strength	Pack size	Price and subsidy
Clopidogrel	Arrow-Clopidogrel	75 mg	28 tab	\$45.00

- The price and subsidy (ex-manufacturer, excluding GST) of Arrow-Clopidogrel would decrease from 1 March 2009 as follows:


Chemical	Brand	Strength	Pack size	Price and subsidy
Clopidogrel	Arrow-Clopidogrel	75 mg	28 tab	\$35.00

- Arrow-Clopidogrel would be listed under the current clopidogrel Special Authority criteria in Section B of the Pharmaceutical Schedule.
- Arrow-Clopidogrel would have subsidy protection in Section B of the Pharmaceutical Schedule until 1 March 2009.
- Arrow-Clopidogrel would have delisting protection in Section B and Section H of the Pharmaceutical Schedule until 1 March 2010.
- The subsidy for the Plavix brand of clopidogrel in Section B of the Pharmaceutical Schedule would be reduced by reference pricing it to Arrow-Clopidogrel as follows:

Chemical	Brand	Strength	Pack size	Subsidy per pack		
				As at 1 June 2007	From 1 March 2008	From 1 March 2009
Clopidogrel	Plavix	75 mg	28 tab	\$73.38	\$45.00	\$35.00

PHARMAC welcomes feedback on this proposal. If you wish to make comments regarding this proposal for the PHARMAC Board to consider when making its decision about whether to accept this proposal, please forward them to Stephen Woodruffe at PHARMAC by **5:00 pm, Wednesday, 13 July 2007**. If you have any questions regarding this proposal, please contact me on (04) 916 7555 or Stephen.Woodruffe@PHARMAC.govt.nz.

Yours sincerely



Stephen Woodruffe
Therapeutic Group Manager